Ab­Cellera ac­quires trans­mem­brane pro­tein pro­duc­er; Com­pass gains psy­che­del­ic IP port­fo­lio

Cana­di­an an­ti­body shop Ab­Cellera ac­quired Mass­a­chu­setts biotech Tetra­Ge­net­ics in an all-cash trans­ac­tion. While more spe­cif­ic de­tails were not made pub­licly avail­able, Ab­Cellera did say in a state­ment that the ac­qui­si­tion in­cludes an up­front pay­ment and po­ten­tial mile­stone pay­ments based on tech­ni­cal achieve­ments, suc­cess­ful R&D and com­mer­cial­iza­tion.

Found­ed in 2004, Tetra­Ge­net­ics spe­cial­izes in pro­tein pro­duc­tion — specif­i­cal­ly trans­mem­brane pro­teins, which have proven to be dif­fi­cult to pro­duce in the past. Where Tetra­Ge­net­ics comes in­to the equa­tion with Ab­Cellera is that Tetra­Ge­net­ics can make enough trans­mem­brane pro­teins to sup­port an­ti­body dis­cov­ery.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.